The U.K.'s Competition and Markets Authority said it will investigate Medtronic PLC's acquisition of certain assets of Johnson & Johnson's insulin delivery business, Animas Corp.
The Brunswick, N.J.-based drugmaker said in October 2017 that it was exiting the insulin pump market and offered to transfer its patients to Medtronic products.
The regulator said it had sufficient information that the transaction may hurt competition in the U.K. thus warranted an initial investigation.
The CMA will conduct a phase 1 investigation and will decide whether to proceed to an in-depth phase 2 investigation by June 6.
The investigators have ordered Dublin-based Medtronic to halt the integration of Animas assets in the U.K. until the investigation is complete.